Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 6, 2013, Pages 1291-1300

  Chang, Pi Yueh ^a   Kuo, Yung Bin ^a   Wu, Tsu Lan ^a   Liao, Chun Ta ^a   Sun, Yu Chen ^a   Yen, Tzu Chen ^a   Chan, Err Cheng ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

C reactive protein (CRP); E selectin; Inflammation; Leukoplakia; Metalloprotease 9 (MMP 9); Oral cavity cancer

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; METALLOPROTEINASE; SERUM AMYLOID A; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; E-SELECTIN; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; LEUKOPLAKIA; MALE; MATRIX METALLOPROTEINASE 9; MOUTH NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84882407393     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0504     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Cancer Registry Annual Report, 2008. Taiwan Department of Health, Available from: . Released on December, 2010.
3. Kuffer R, Lombardi T. Premalignant lesions of the oral mucosa. A discussion about the place of oral intraepithelial neoplasia (OIN). Oral Oncol 2002;38:125-30.
4. Van Der Waal I, Schepman KP, Van Der Meij EH, Smeele LE. Oral leukoplakia: a clinicopathological review. Oral Oncol 1997;33:291-301.
5. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol 2003;39:770-80.
6. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia-a systematic review and meta-analysis. Head Neck 2009;31:1600-9.
7. Yang YH, Lee HY, Tung S, Shieh T Y. Epidemiological survey of oral submucous fibrosis and leukoplakia in aborigines of Taiwan. J Oral Pathol Med 2001;30:213-9.
8. 2010-2013 National cancer prevention program. Taiwan Department of Health, Available from: . Released November, 2009.
9. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009;73:764-71.
10. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Preoperative 18Ffluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009;74:1054-61.
11. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, et al. Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. Ann Surg Oncol 2009;16:159-70.
12. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer 2000;82:1871-4.
13. Hoffmann J, Munz A, Krimmel M, Alfter G. Intraoperative and postoperative kinetics of serum tumor markers in patients with oral carcinoma. J Oral Maxillofac Surg 1998;56:1390-3.
14. Kurokawa H, Yamashita Y, Tokudome S, Kajiyama M. Combination assay for tumor markers in oral squamous cell carcinoma. J Oral Maxillofac Surg 1997;55:964-6.
15. Wang Z, Feng X, Liu X, Jiang L, Zeng X, Ji N, et al. Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis. BMC Genomics 2009;10:383.
16. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005;51:2236-44.
17. Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics 2008;7:1639-50.
18. Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 2008;44:1093-9.
19. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomark Prev 2007;16:102-7.
20. Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, et al. Proteomic identification of salivary transferring as a biomarker for early detection of oral cancer. Anal Chim Acta 2010;681:41-8.
21. Jablonska E, Piotrowski L, Grabowska Z. Serum levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res 1997;3:126-9.
22. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929-35.
23. Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL, et al. Prognostic cytokine markers in peripheral blood for oral cavity squamous cell carcinoma identified by multiplexed immunobead-based profiling. Clin Chim Acta 2011;412:980-7.
24. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
25. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-80.
26. Van Kempen LC, De Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer 2006;42:728-34.
27. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010;31:37-49.
28. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
29. Edge SB, Byrd Dr, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual, 7th ed. Springer, 2010.
30. Wu TL, Tsao KC, Chang CP, Li CN, Sun CF, Wu JT. Development of ELISA on microplate for serum C-reactive protein and establishment of age-dependent normal reference range. Clin Chim Acta 2002;322:163-8.
31. Tsao KC, Chang PY, Li CC, Wu TL, Sun CF, Wu JT. Development of a microplate ELISA for circulating E-selectin: assay characterization, comparison with a commercial kit, wand establishment of normal reference values. J Clin Lab Anal 2003;17:97-101.
32. Chang PY, Wu TL, Tsao KC, Li CC, Sun CF, Wu JT. Microplate ELISAs for soluble VCAM-1 and ICAM-1. Ann Clin Lab Sci 2005;35:312-7.
33. Wu TL, Tsai IC, Chang PY, Tsao KC, Sun CF, Wu LL, et al. Establishment of an in-house ELISA and the reference range for serum amyloid A (SAA): complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta 2007;376:72-6.
34. Chang MC, Chiang CP, Lin CL, Lee JJ, Hahn LJ, Jeng JH. Cell-mediated immunity and head and neck cancer: with special emphasis on betel quid chewing habit. Oral Oncol 2005;41:757-75.
35. Chang SS, Califono J. Current status of biomarkers in head and neck cancer. J Surg Oncol 2008;97:640-3.
36. Reddy S, Reddy M, Shyam ND. Tumour markers in oral neoplasia. Indian J Dent Adv 2010;2:103-14.
37. Tortorici S, Mauro A, Burruano F, Difalco P, Leone A, Gerbino A, et al. Matrix metalloproteinase-2 matrix metalloproteinase-9 and inducible nitric oxide synthase in oral leukoplakia: immunohistochemistry and RT-PCR analysis. J Biol Regul Homeost Agents 2008;22:125-30.
38. Kato K, Hara A, Kuno T, Kitaori N, Zhi HL, Mori H, et al. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol 2005;131:340-6.
39. Samara GJ, Lawrence DM, Chiarelli CJ, Valentino MD, Lyubsky S, Zucker S, et al. CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 2004;214:231-41.
40. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol 2009;45:647-53.
41. Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine 2005;30:93-9.
42. Gary Lee YC, Melkerneker D, Thompson PJ, Light RW, Lane KB. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 2002;165:88-94.
43. Ewa J, Leszek P, Zyta G. Serum levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res 1997;3:126-9.
44. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-79.
45. De Oliveira MV, Fraga CA, Gomez RS, Paula AM. Immunohistochemical expression of interleukin-4, -6, -8, and -12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma. Head Neck 2009;31:1439-46.
46. Rao SK, Pavicevic Z, Du Z, Kim J-G, Fan M, Jiao Y, et al. Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 2010;285:32512-21.
47. Grandis JR, Snyderman CH, Johnson JT, Yu VL, D'Amico F. Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer. Cancer 1992;70:2166-70.
48. Roxburgh CS, McMillan DC. Role of systemic inflammatory responses in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-63.